01 August
2024
Graft Polymer (UK)
Plc
("Graft Polymer" or the
"Company")
Director
resignation
Graft Polymer (UK) Plc (LON: GPL),
an innovative biopolymer drug delivery systems development company,
announces the resignation, with immediate effect, of Mr. Victor
Bolduev from its board of directors and from his role as the
Company's Chief Technology Officer. Mr Bolduev's resignation
follows :
a) the Company's
divestiture of its industrial plastics business unit, Graft Polymer
D.O.O., in early May 2024; and
b) the Company's
prioritisation of opportunities in the healthcare industry,
including the recently announced collaboration agreement with Awakn
Life Sciences Corp (CSE:AWKN OTCQB:AWKNF) and the appointment, on
30 July 2024, of Professor David Nutt as the Company's Senior
Scientific Adviser.
Enquiries:
Graft Polymer (UK) Plc
Anthony Tennyson, CEO and Executive Director
Email: anthonytennyson@graftpolymer.co.uk
Yifat Steuer, CFO and Executive Director
Email: yifat@graftpolymer.co.uk
Allenby Capital (Broker)
Nick Naylor
/ Liz Kirchner (Corporate Finance) | Guy McDougall
(Sales)
+44 (0) 20 3328
5656
About Graft Polymer (UK) Plc
Graft Polymer plc ("Graft Polymer")
(LON: GPL) is an innovative biopolymer drug delivery systems
development company dedicated to enabling biopharmaceutical
companies to enhance the effectiveness of their therapeutics. Our
proprietary platform, a bioabsorbable self-nanoemulsifying drug
delivery system (SNEDDS), represents a cutting-edge solution in
drug delivery technology. By integrating active pharmaceutical
ingredients (APIs) into our novel, patented delivery systems, we
enable clients to improve the pharmacokinetics, bioavailability,
and stability of their therapeutics..
For more information, please visit
www.graftpolymer.co.uk.
